irbesartan brands

17 registered brands containing irbesartan in Tanzania.

Irbesartan

PubChem CID 3749

Molecular formula: C25H28N6O

Irbesartan prevents angiotensin II binding to the AT<sub>1</sub> receptor in tissues like vascular smooth muscle and the adrenal gland. Irbesartan and its active metabolite bind the AT<sub>1</sub> receptor with 8500 times more affinity than they bind to the AT<sub>2</sub> receptor. Irbesartan's prevention of angiotensin II binding causes vascular smooth muscle relaxation and prevents the secretion of aldosterone, lowering blood pressure. Angiotensin II would otherwise bind to the AT<sub>1</sub> receptor, inducing vasoconstriction and aldosterone secretion, raising blood pressure. Angiotensin II is a potent vasoconstrictor formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system (RAS) and also stimulates aldosterone synthesis and secretion by adrenal cortex, cardiac contraction, renal resorption of sodium, activity of the sympathetic nervous system, and smooth muscle cell growth. Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 angiotensin II receptor. There is also an AT2 receptor in many tissues, but it is not involved in cardiovascular homeostasis. Irbesartan is a specific competitive antagonist of AT1 receptors with a much greater affinity (more than 8500-fold) for the AT1 receptor than for the AT2 receptor and no agonist activity. Blockade of the AT1 receptor removes the negative feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and circulating angiotensin II do not overcome the effects of irbesartan on blood pressure. Irbesartan does not inhibit ACE or renin or affect other hormone receptors or ion channels known to be involved in the cardiovascular regulation of blood pressure and sodium homeostasis. Because irbesartan does not inhibit ACE, it does not affect the response to bradykinin; whether this has clinical relevance is not known.

Source: PubChem (NCBI) · compound 3749

Product Manufacturer Status Country
Co-Irda
Film Coated Tablet
Nobel Ilaç Registered/Compliant Tanzania
Co-Irda
Film Coated Tablet
Nobel Ilaç Registered/Compliant Tanzania
IRBEZYD H 150/12.5
Tablets
- Registered/Compliant Tanzania
Irbis HT 300/12.5
Tablets
Hetero Labs Registered/Compliant Tanzania
IRBIS 150
Tablets
Hetero Labs Registered/Compliant Tanzania
IRBIS 300
Tablets
Hetero Labs Registered/Compliant Tanzania
IRBIS-H 150
Tablets
Hetero Labs Registered/Compliant Tanzania
Irda 150 mg
Film Coated Tablet
Nobel Ilac Registered/Compliant Tanzania
Irda 300 mg
Film Coated Tablet
Nobel Ilac Registered/Compliant Tanzania
IROVASC 150
Oral tablet
- Registered/Compliant Tanzania
Irovel 150 mg Tablet
Oral tablet
Sun Pharma Registered/Compliant Tanzania
Irovel H
Oral tablet
Sun Pharma Registered/Compliant Tanzania
Irovel Tablets
Oral tablet
Sun Pharma Registered/Compliant Tanzania
Omcasart I 300
Oral tablet
Saitech Medicare Pvt. Ltd Registered/Compliant Tanzania
OMCASART-I 150
Oral tablet
Acme Laboratories Registered/Compliant Tanzania
SciProvel
Film Coated Tablet
Macleods Pharmaceuticals Limited Registered/Compliant Tanzania
SciProvel
Film Coated Tablet
Macleods Pharmaceuticals Limited Registered/Compliant Tanzania